Literature DB >> 22675478

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation.

Fabian Käsermann1, David J Boerema, Monika Rüegsegger, Andreas Hofmann, Sandra Wymann, Adrian W Zuercher, Sylvia Miescher.   

Abstract

It has been proposed that the anti-inflammatory effects of intravenous immunoglobulin (IVIG) might be due to the small fraction of Fc-sialylated IgG. In this study we biochemically and functionally characterized sialic acid-enriched IgG obtained by Sambucus nigra agglutinin (SNA) lectin fractionation. Two main IgG fractions isolated by elution with lactose (E1) or acidified lactose (E2) were analyzed for total IgG, F(ab')(2) and Fc-specific sialic acid content, their pattern of specific antibodies and anti-inflammatory potential in a human in vitro inflammation system based on LPS- or PHA-stimulated whole blood. HPLC and LC-MS testing revealed an increase of sialylated IgG in E1 and more substantially in the E2 fraction. Significantly, the increased amount of sialic acid residues was primarily found in the Fab region whereas only a minor increase was observed in the Fc region. This indicates preferential binding of the Fab sialic acid to SNA. ELISA analyses of a representative range of pathogen and auto-antigens indicated a skewed antibody pattern of the sialylated IVIG fractions. Finally, the E2 fraction exerted a more profound anti-inflammatory effect compared to E1 or IVIG, evidenced by reduced CD54 expression on monocytes and reduced secretion of MCP-1 (CCL2); again these effects were Fab- but not Fc-dependent. Our results show that SNA fractionation of IVIG yields a minor fraction (approx. 10%) of highly sialylated IgG, wherein the sialic acid is mainly found in the Fab region. The tested anti-inflammatory activity was associated with Fab not Fc sialylation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22675478      PMCID: PMC3366990          DOI: 10.1371/journal.pone.0037243

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  35 in total

Review 1.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 2.  Mechanisms of action of intravenous immunoglobulins.

Authors:  Anne Baerenwaldt; Markus Biburger; Falk Nimmerjahn
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

Review 3.  The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.

Authors:  Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2010-12-24       Impact factor: 10.793

4.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

Review 5.  Intravenous immunoglobulin a natural regulator of immunity and inflammation.

Authors:  Stanley C Jordan; Mieko Toyoda; Ashley A Vo
Journal:  Transplantation       Date:  2009-07-15       Impact factor: 4.939

Review 6.  Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.

Authors:  H-P Hartung; L Mouthon; R Ahmed; S Jordan; K B Laupland; S Jolles
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

7.  Cutting edge: intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcγRIIIA-dependent mechanisms.

Authors:  Luiza M Araujo; Angélique Chauvineau; Ren Zhu; Séverine Diem; Elvire A Bourgeois; Anaïs Levescot; Michel Huerre; Jean-Marc Gombert; Jagadeesh Bayry; Marc Daëron; Pierre Bruhns; Srini V Kaveri; André Herbelin
Journal:  J Immunol       Date:  2011-02-11       Impact factor: 5.422

8.  IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes.

Authors:  Jean-François Séïté; Divi Cornec; Yves Renaudineau; Pierre Youinou; Rizgar A Mageed; Sophie Hillion
Journal:  Blood       Date:  2010-06-01       Impact factor: 22.113

Review 9.  Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders.

Authors:  P Imbach; A H Lazarus; T Kühne
Journal:  Vox Sang       Date:  2009-10-11       Impact factor: 2.144

10.  A close look at human IgG sialylation and subclass distribution after lectin fractionation.

Authors:  Johannes Stadlmann; Alfred Weber; Martin Pabst; Heinz Anderle; Renate Kunert; Hartmut J Ehrlich; Hans Peter Schwarz; Friedrich Altmann
Journal:  Proteomics       Date:  2009-09       Impact factor: 3.984

View more
  39 in total

1.  Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.

Authors:  Benjamin M Fiebiger; Jad Maamary; Andrew Pincetic; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.

Authors:  B J B Lewis; D Leontyev; A Neschadim; M Blacquiere; D R Branch
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

3.  Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Authors:  Ian K Campbell; Sylvia Miescher; Donald R Branch; Patrick J Mott; Alan H Lazarus; Dongji Han; Eugene Maraskovsky; Adrian W Zuercher; Anton Neschadim; Danila Leontyev; Brent S McKenzie; Fabian Käsermann
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

4.  Will sialylation change intravenous immunoglobulin therapy in the future?

Authors:  F Käsermann; I K Campbell
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

5.  Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.

Authors:  I Schwab; F Nimmerjahn
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

7.  Highly parallel characterization of IgG Fc binding interactions.

Authors:  Austin W Boesch; Eric P Brown; Hao D Cheng; Maame Ofua Ofori; Erica Normandin; Peter A Nigrovic; Galit Alter; Margaret E Ackerman
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

8.  Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG.

Authors:  Sumit Kumar; Jagmohan Singh; Ramalinga Kedika; Fabian Mendoza; Sergio A Jimenez; Erik S Blomain; Anthony J DiMarino; Sidney Cohen; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-12       Impact factor: 4.052

Review 9.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

10.  Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors.

Authors:  Andrea Franco; Bazarragchaa Damdinsuren; Tomoko Ise; Jessica Dement-Brown; Huifang Li; Satoshi Nagata; Mate Tolnay
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.